• Explore /
  • Poster
  • / Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.

Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.

Abstract Video & Slides Poster

Authors

Arndt Vogel

Arndt Vogel

Hannover Medical School, Hannover, Germany

Arndt Vogel , Lorenza Rimassa , Hui-Chuan Sun , Ghassan K. Abou-Alfa , Anthony B. El-Khoueiry , David James Pinato , Monica Daigl , Javier Sanchez Alvarez , Panos Orfanos Sr., Michael Leibfried , Marie-Hélène Blanchet Zumofen , Vincent Gaillard , Philippe Merle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4585)

DOI

10.1200/JCO.2020.38.15_suppl.4585

Abstract #

4585

Poster Bd #

193

Abstract Disclosures

Similar Posters

First Author: Claudia A.M. Fulgenzi

First Author: Claudia A.M. Fulgenzi

First Author: David Trueman

First Author: Han Chong Toh